GCP
NVS icon

GSA Capital Partners’s Novartis NVS Stock Holding History

GSA Capital Partners’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,670
Closed -$424K – 1810
2017
Q2 		$424K Buy
+5,670
New +$402K 0.03% 1086
2016
Q2 		– Sell
-3,552
Closed -$231K – 1856
2016
Q1 		$231K Buy
+3,552
New +$242K 0.01% 1432

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GSA Capital Partners's NVS Position: Q3 2017 in Review

GSA Capital Partners sold out of Novartis (NVS) in Q3 2017, closing a stake of 5,670 shares — an estimated $424K sold.

GSA Capital Partners first reported a position in NVS in Q1 2016 and held it in 2 quarters. The position peaked at $424K in Q2 2017. 937 funds tracked by Wall St. Rank hold NVS as of Q3 2017.

  • GSA Capital Partners reported no remaining Novartis position as of Q3 2017 after selling out during the quarter.
  • GSA Capital Partners sold 5,670 Novartis shares in Q3 2017, an estimated $424K.
  • GSA Capital Partners first reported a position in Novartis in Q1 2016 and held it in 2 quarters.
  • GSA Capital Partners's Novartis position peaked at $424K in Q2 2017.
  • 937 funds tracked by Wall St. Rank held Novartis as of Q3 2017.

Based on GSA Capital Partners's 13F filing for Q3 2017, filed 20 Nov 2017.